Bionxt Solutions Secures Key European Patent for Drug Delivery Platform

Bionxt Solutions gains European patent for its sublingual Cladribine film, a key step for its MS treatment strategy and upcoming clinical trials.

Bionxt Solutions has achieved a significant legal milestone that underpins its future commercial strategy. The European Patent Office has granted formal approval for the company's proprietary drug delivery technology, moving its innovative multiple sclerosis treatment closer to potential market entry.

A Foundation for Commercial Strategy

The granted European patent, numbered 4539857, provides legal protection for Bionxt's core technology until at least mid-June 2043 across the designated European countries. This protection covers a novel method of administering the drug Cladribine via a sublingual oral thin film (ODF). The system is specifically designed for treating multiple sclerosis and represents the central asset in the company's clinical development pipeline.

According to CEO Hugh Rogers, this European decision establishes the essential groundwork for long-term marketing plans. The formal patent grant is not merely a procedural step but a critical enabler for the company's upcoming phase of development and partnership discussions.

Advancing Clinical and Global Ambitions

With the legal framework now solidified in Europe, Bionxt is preparing to initiate human bioequivalence studies. The objective of this clinical work is to advance the platform through trials, aiming to demonstrably improve patient adherence and treatment outcomes in the neurodegenerative field.

Concurrently, the company is progressing its global intellectual property strategy. Following a prior success with the Eurasian Patent Organization, Bionxt is now pursuing a "Fast-Track" status for the same technology with United States authorities.

Market Performance and Partnership Pathway

On the trading front, Bionxt shares presented a stable picture on Wednesday, closing at €0.38. This price level positions the equity slightly above its 50-day moving average of €0.37 and reflects a moderate 30-day gain of 3.52 percent.

The formalized European patent protection provides Bionxt with a verified legal asset. This security is a mandatory prerequisite for imminent licensing and partnership negotiations within the healthcare industry, as management concurrently prepares to enter the next phase of clinical testing.